WDR21C inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the WDR21C protein, a member of the WD repeat-containing protein family. WDR21C is characterized by its WD40 repeat domains, which are highly conserved structural motifs that facilitate protein-protein interactions and the formation of multiprotein complexes. These complexes are involved in regulating a wide range of cellular processes, such as signal transduction, gene expression, and protein degradation. WDR21C is believed to play a critical role in organizing and stabilizing these complexes, particularly in processes related to chromatin remodeling and DNA repair, where precise control of protein interactions is essential for maintaining cellular integrity. By inhibiting WDR21C, these compounds can disrupt the assembly and function of such protein complexes, potentially altering key molecular pathways involved in maintaining cellular homeostasis.
The mechanism of action of WDR21C inhibitors typically involves binding to the WD40 repeat domains or other critical functional regions of the WDR21C protein, preventing it from engaging with its interacting partners. This inhibition interferes with WDR21C's ability to mediate complex cellular functions, such as chromatin organization and protein turnover, by disrupting the multiprotein assemblies it regulates. Researchers utilize WDR21C inhibitors to investigate the specific biological roles of this protein, exploring how its inhibition impacts molecular pathways associated with cellular organization, genome maintenance, and protein homeostasis. By studying these inhibitors, scientists gain a deeper understanding of how WDR21C and similar WD repeat-containing proteins contribute to the regulation of cellular architecture and dynamic protein interactions, offering insights into the fundamental mechanisms governing cellular structure and function across different biological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 is a potent inhibitor of NEDD8-activating enzyme (NAE), indirectly inhibiting the function of DCAF4L2 by preventing the neddylation of CUL4, which is crucial for DCAF4L2-mediated ubiquitination. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin interferes with multiple signaling pathways and can indirectly influence DCAF4L2 function by modulating proteasomal degradation and ubiquitination processes. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can indirectly affect DCAF4L2 activity by inhibiting the degradation of proteins targeted by the CUL4-DDB1-DCAF4L2 complex. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, another proteasome inhibitor, functions similarly to MG132 and can modulate the activity of proteins involved in the DCAF4L2 pathway. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide and its analogs can affect the ubiquitin-proteasome system, indirectly influencing DCAF4L2-mediated protein ubiquitination. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide, a derivative of thalidomide, also affects the ubiquitin-proteasome system, potentially altering DCAF4L2 activity. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $143.00 $312.00 $468.00 $1248.00 $1997.00 | 1 | |
Pomalidomide, related to thalidomide and lenalidomide, has a similar mechanism of action and may influence DCAF4L2 activity. | ||||||
VER 155008 | 1134156-31-2 | sc-358808 sc-358808A | 10 mg 50 mg | $203.00 $842.00 | 9 | |
VX-11e is an ERK inhibitor that can indirectly affect DCAF4L2 by modulating signaling pathways that intersect with DCAF4L2-related processes. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
AZD6244, also an inhibitor of the ERK pathway, may have an indirect influence on DCAF4L2's role in protein ubiquitination. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor with broad targets, potentially affecting pathways that indirectly influence DCAF4L2 activity. | ||||||